myalgic encephalomeyelitis/chronic fatigue syndrome
MONDO:0005404
A medical condition characterized by long-term fatigue and other symptoms that limit a person's ability to carry out ordinary daily activities.
Disease research snapshot
CureCurrent currently links 15 distinct registered clinical trials to myalgic encephalomeyelitis/chronic fatigue syndrome through its MONDO disease mappings. 3 of those studies have the registry status “recruiting” (20%). These are registry statuses, not availability guarantees, study results or evidence of effectiveness.
The leading sponsor shown in this linked dataset is University of Alabama at Birmingham, associated with 2 distinct linked trials. This is a count of records, not a ranking of the sponsor's scientific quality.
The highest-count mapped research city in the current result is Birmingham, United States. Only site locations available in the published registry projection are counted; some trial sites may be missing or outdated.
The most frequently mapped drug concept in the current linked trials is citalopram (1 distinct trials). This describes what has been studied, not a recommended treatment.
Numbers are derived from CureCurrent's current ClinicalTrials.gov projection and conservative MONDO/RxNorm mappings. See sources, counting rules and limitations and verify eligibility or clinical findings with the original study record.
Research intelligence
Directly mapped studies only · unique clinical trialsCurrent registry observations. Phase counts may overlap. Study start dates are not registry registration dates. Investigational interventions are not approved-treatment recommendations.
Medications under investigation
Verified disease and drug mappings that co-occur within the same study; not evidence of effectiveness.
MONDO disease family
Recruiting studies by city
Trial status
Trial phase
Study start year
Investigated drug interventions
Myalgic encephalomyelitis/chronic fatigue syndrome
Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a disabling chronic illness. People with ME/CFS experience profound fatigue that does not go away with rest, as well as problems with sleep and memory or concentration. The hallmark symptom is post-exertional malaise (PEM), a worsening of the illness that can start immediately or up to days after even minor physical or mental activity. This "crash" can last hours, days or several months. Further common symptoms include orthostatic intolerance—dizziness or faintness when upright—and pain. The cause of the disease is unknown. ME/CFS often starts after an infection, such as infectious mononucleosis. Studies find impairment in the nervous and immune systems, as well as in energy production. A diagnosis is established with the presence of clinical symptoms and systematic differential diagnosis, as there is no verified diagnostic laboratory test or imaging procedure available. ME/CFS symptoms can improve or worsen over time, but a full recovery is uncommon. No therapies or medications are approved to treat the cause of the condition, and treatment or management is aimed at relieving symptoms. Pacing of activities can help avoid PEM which can worsen symptoms for extended periods, and counselling may help in coping with the illness. Before the COVID-19 pandemic, ME/CFS affected two to nine out of every 1,000 people, depending on the diagnostic criteria. Since the pandemic began, with the similarity of long COVID, many more people fit a diagnosis of ME/CFS. It occurs more often in women than in men and is more commo...
Background only. Canonical identity remains MONDO; clinical-trial relationships come from ClinicalTrials.gov.Clinical trials
15 shownDrugs being studied
Research locations
Leading sponsors
How to interpret this record
CureCurrent links normalized diseases, medicines, registry study labels, sponsors and research sites. A link is not the same as a finding of clinical effectiveness. Our research guides explain how to compare studies, decode RxNorm identities, and avoid over-interpreting site and trial counts. See the published database coverage for mapping completeness.
Disease identity and terminology: MONDO. Trial relationships: ClinicalTrials.gov.